Imricor brings Johnson & Johnson veteran onto board, hits milestone

Imricor recently announced that it has brought a 19-year Johnson & Johnson veteran onto its board, and hit a milestone with its technology for MRI-guided cardiac procedures.

Based in the Minneapolis area in Burnsville, Imricor announced yesterday that it is bringing Aldo Denti onto its board. Denti recently stepped down as group chair of Global Orthopedics at Johnson & Johnson MedTech to become CCO at Dentsply Sirona. (J&J is now in the process of separating its DePuy Synthes orthopedics business from the rest of the company.)

“Throughout my 30-year career at companies such as Medtronic and Johnson & Johnson MedTech, I have witnessed remarkable innovations that have reshaped the landscape of healthcare and improved millions of lives. Yet it is rare to encounter a technology with the potential to redefine an entire field as profoundly as Imricor’s MRI-guided platform. What Imricor has developed is not an incremental improvement. It represents a paradigm shift in the way electrophysiology and other interventional procedures are performed,” Denti said in a news release.

“I am deeply impressed with the exceptional management team and board, whose vision and dedication have brought the technology to this point and are driving the company forward. And I am honored to join the board at this pivotal moment, as Imricor transitions from innovation to global commercialization. With my extensive experience in the medical device sector, I am eager to contribute to the company’s growth and help navigate the opportunities of commercialization. Together, we have the opportunity to establish a new global standard of care in cardiac interventions and to unlock extraordinary long-term value for patients, hospitals, and shareholders.”

Said Imricor CEO Steve Wedan: “His appointment underscores our commitment to building a world-class leadership team capable of executing on our vision: to make MRI-guided cardiac procedures the new global standard of care. With Aldo’s strategic insight and shared passion for advancing patient outcomes, Imricor is exceptionally well-positioned for the next phase of its journey.”

Just last week, Imricor announced that an Amsterdam University Medical Centre team in the Netherlands successfully completed the first ischemic ventricular tachycardia (VT) ablation ever performed under real-time MRI guidance in an iCMR lab.

Dr. Michiel Kemme, who performed the VT ablation, said: “Thanks to the interventional MRI, we can see exactly in 3D where the sheath and ablation catheter are. This allowed us to move from the right atrium to the left atrium through the septum. It gives us much more information than the usual method.”